PURPOSE: We evaluated our experience with renal cortical tumors to determine whether tumor size is associated with malignant histology and/or nuclear grade. MATERIALS AND METHODS: We identified 2,675 patients treated surgically at our institution for renal cell carcinoma or a benign tumor between 1989 and 2007. Histological subtype and tumor size were obtained from our kidney cancer database and logistic regression analysis was performed. RESULTS: Of the 2,675 tumors 311 (12%) were benign and 2,364 (88%) were renal cell carcinoma. The OR for the association of malignancy with tumor size was 1.16 (95% CI 1.11-1.22, p <0.001), indicating that each 1 cm increase in tumor size was associated with a 16% increase in the odds of malignancy. The incidence of benign tumors decreased from 38% for tumors less than 1 cm to 7% for tumors 7 cm or greater. In patients with clear cell renal cell carcinoma each 1 cm increase in tumor size increased the odds of high grade disease (Fuhrman grade 3-4) compared with low grade disease (Fuhrman grade 1-2) by 25% (OR 1.25, 95% CI 1.21-1.30, p <0.001). In this subset the incidence of high grade lesions increased from 0% for tumors less than 1 cm to 59% for tumors greater than 7 cm. CONCLUSIONS: Our results confirm previous observations suggesting that the risks of malignancy and high grade tumors increase with tumor size. Patients with small renal masses are at low risk for harboring a high grade clear cell malignancy, which may be useful during initial consultation.
PURPOSE: We evaluated our experience with renal cortical tumors to determine whether tumor size is associated with malignant histology and/or nuclear grade. MATERIALS AND METHODS: We identified 2,675 patients treated surgically at our institution for renal cell carcinoma or a benign tumor between 1989 and 2007. Histological subtype and tumor size were obtained from our kidney cancer database and logistic regression analysis was performed. RESULTS: Of the 2,675 tumors 311 (12%) were benign and 2,364 (88%) were renal cell carcinoma. The OR for the association of malignancy with tumor size was 1.16 (95% CI 1.11-1.22, p <0.001), indicating that each 1 cm increase in tumor size was associated with a 16% increase in the odds of malignancy. The incidence of benign tumors decreased from 38% for tumors less than 1 cm to 7% for tumors 7 cm or greater. In patients with clear cell renal cell carcinoma each 1 cm increase in tumor size increased the odds of high grade disease (Fuhrman grade 3-4) compared with low grade disease (Fuhrman grade 1-2) by 25% (OR 1.25, 95% CI 1.21-1.30, p <0.001). In this subset the incidence of high grade lesions increased from 0% for tumors less than 1 cm to 59% for tumors greater than 7 cm. CONCLUSIONS: Our results confirm previous observations suggesting that the risks of malignancy and high grade tumors increase with tumor size. Patients with small renal masses are at low risk for harboring a high grade clear cell malignancy, which may be useful during initial consultation.
Authors: William C Huang; Andrew S Levey; Angel M Serio; Mark Snyder; Andrew J Vickers; Ganesh V Raj; Peter T Scardino; Paul Russo Journal: Lancet Oncol Date: 2006-09 Impact factor: 41.316
Authors: S E Bleeker; H A Moll; E W Steyerberg; A R T Donders; G Derksen-Lubsen; D E Grobbee; K G M Moons Journal: J Clin Epidemiol Date: 2003-09 Impact factor: 6.437
Authors: Igor Frank; Michael L Blute; John C Cheville; Christine M Lohse; Amy L Weaver; Horst Zincke Journal: J Urol Date: 2003-12 Impact factor: 7.450
Authors: Chaitanya R Divgi; Neeta Pandit-Taskar; Achim A Jungbluth; Victor E Reuter; Mithat Gönen; Shutian Ruan; Christine Pierre; Andrew Nagel; Daniel A Pryma; John Humm; Steven M Larson; Lloyd J Old; Paul Russo Journal: Lancet Oncol Date: 2007-04 Impact factor: 41.316
Authors: Inderbir S Gill; Surena F Matin; Mihir M Desai; Jihad H Kaouk; Andrew Steinberg; Ed Mascha; Julie Thornton; Mahmoud H Sherief; Brenda Strzempkowski; Andrew C Novick Journal: J Urol Date: 2003-07 Impact factor: 7.450
Authors: Matthew S Davenport; Eric M Hu; Andrew Zhang; Atul B Shinagare; Andrew D Smith; Ivan Pedrosa; Samuel D Kaffenberger; Stuart G Silverman Journal: Abdom Radiol (NY) Date: 2019-04
Authors: Boyd R Viers; R Houston Thompson; Christine M Lohse; John C Cheville; Bradley C Leibovich; Stephen A Boorjian; Matthew K Tollefson Journal: World J Urol Date: 2016-04-06 Impact factor: 4.226
Authors: Mark W Ball; Michael A Gorin; Sam B Bhayani; Craig G Rogers; Michael D Stifelman; Jihad H Kaouk; Homayoun Zargar; Susan Marshall; Jeffrey A Larson; Haider M Rahbar; Bruce J Trock; Phillip M Pierorazio; Mohamad E Allaf Journal: Urol Oncol Date: 2014-12-11 Impact factor: 3.498
Authors: Michael Organ; Michael Jewett; Joan Basiuk; Christopher Morash; Stephen Pautler; D Robert Siemens; Simon Tanguay; Martin Gleave; Darrell Drachenberg; Raymond Chow; Joseph Chin; Andrew Evans; Neil Fleshner; Brenda Gallie; Masoom Haider; John Kachura; Antonio Finelli; Ricardo A Rendon Journal: Can Urol Assoc J Date: 2014 Jan-Feb Impact factor: 1.862
Authors: Hebert Alberto Vargas; Holly G Delaney; Eithne M Delappe; Ya Wang; Junting Zheng; Chaya S Moskowitz; Yongqiang Tan; Binsheng Zhao; Lawrence H Schwartz; Hedvig Hricak; Paul Russo; Oguz Akin Journal: J Magn Reson Imaging Date: 2012-11-13 Impact factor: 4.813